Renal transplant recipients between 65-75 years of age, on stable immunosuppression. who previously (>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23). Cause or renal failure was either DMII or HTN.

Persons with DMII or hypertension but normal renal function between ages 65-75 years of age

Healthy persons between the ages 65-75 who previously (>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23)

Persons between the ages 65-75 with DMII or hypertension but normal renal function who previously (>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23)

Healthy persons between the ages 35-45 who previously (>1 year prior) received the 23 valent pneumococcal polysaccharide vaccine (pneumovax23) or are willing to receive PPV23 and 1 year later Prevnar 13.

Renal Transplantation

Aging

FDA approved pneumococcal polysaccharide vaccine containing capsular polysaccharide of 23 different pneumococcal serotypes. Only group 5 will potentially receive this as an intervention.

23 valent pneumococcal polysaccharide vaccine

FDA approved pneumococcal polysaccharide vaccine containing capsular polysaccharide of 13 different pneumococcal serotypes conjugated to CRM197. Only group 5 will receive this as an intervention. In all other groups Prevnar 13 will be given as standard of care.

13 valent conjugated pneumococcal vaccine

Peripheral blood samples (30-60 mL) will be collected at day 0 (pre-immune), day 7, and day 30 (4 weeks post-PPV23) for groups 1-4 and at days 366, 373 and 396 for group 5. In addition, day 5, and 10 blood samples will be obtained from a limited (n=10) number of elderly RT participants to determine the optimal time point for circulation of PPS-specific B cells. Yearly blood samples will be obtained thereafter for serum antibody and OPA analyses to test longevity of antibody and OPA responses. Samples obtained from days 0, 30 and yearly samples will be used for antibody titers and opsonophagocytic assays. Samples from day 0 (day of vaccination with PCV13) and day 7 will be used for flow cytometric analysis.

Peripheral blood sample

Ralph H. Johnson VA Medical Center, Charleston, SC

Medical University of South Carolina

Pneumococcal Conjugate Vaccine in Aging Renal Transplant

Immune Response to Pneumococcal Vaccination in Aging Renal Transplant Recipients

Measure the anti-pneumococcal polysaccharide IgG antibody response against streptococcus pneumonia serotypes 14, 19A and 23F in serum by ELISA at days 0, 30, 365 and 720

Measure the serum opsonophagocytic activity against streptococcus pneumonia serotypes 14, 19A and 23F on days 0, 30, 365 and 720 by opsonophagocytic assay.

number of polysaccharide specific B cells, and absolute number of IgM memory B cells/mL induced by vaccination with PCV13

Measure the relative gene expression of 56 genes important in antibody production and cell survival per single cell of polysaccharide-specific and non-specific B cells as measured by QTR PCR.

VA Office of Research and Development

Immune response to immunization with Prevnar in elderly aging renal transplant compared to comparison groups: healthy young, healthy elderly, healthy elderly hypertension (HTN) and young renal transplants.

Single 0.5 ml sub-cutaneous dose of 23-valent pneumococcal polysaccharide vaccine (Pneumovax)

Pneumonia, Pneumococcal

23-valent pneumococcal polysaccharide vaccine

Pneumovax

Kilifi District Hospital

Dynamics of the Immune Response in Children to the 23-valent Pneumococcal Capsular Polysaccharide Vaccine (Pneumovax)

Individual response curves for each subject and each antigen will be drawn and the pre-vaccination and the maximum concentrations will be defined. The outcome variable "response threshold" is defined as the time in days to make at least one half of the total IgG response. (The total IgG response is the difference between the maximum observed antibody concentration and the starting concentration). This is a single outcome measure derived as a composite from the different antibody concentrations across the span of the study.

The proportion of the maximal antibody response (on day 11) that has taken place by day 7 will be estimated as follows: proportional rise = C7-C0/C11-C0, where C0, C7 and C11 represent concentrations on day 0, 7 and 11 respectively.

Anthony Scott

Prof Anthony Scott

KEMRI-Wellcome Trust Collaborative Research Program

Invasive Pneumococcal Disease

7-valent pneumococcal conjugated vaccine is given twice with 4 weeks apart

7-valent pneumococcal conjugated vaccine

National Taiwan University Hospital

7-valent Pneumococcal Conjugated Vaccination

1-Year Longitudinal Follow-up Study of Serologic Responses to 7-valent Pneumococcal Conjugated Vaccination and Opsonophagocytic Activities for Streptococcus Pneumoniae Among Patients With Human Immunodeficiency Virus Infection

pneumococcal infections/albuminas

Pneumococcal Conjugate Vaccine in Aging Renal Transplant

Dynamics of the Immune Response in Children to the 23-valent Pneumococcal Capsular Polysaccharide Vaccine (Pneumovax)

7-valent Pneumococcal Conjugated Vaccination

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu